News

To enhance product efficacy, our company collaborates with the Hong Kong Institute of Biotechnology for product improvement. Leveraging the Research and Development Cash Rebate Scheme(CRS) for R&D investment provided by the Innovation and Technology Commission, cell tests were conducted at a local university’s Faculty of Medicine in Hong Kong. These tests successfully elevated the abnormal cell inhibition rate of 3+2 unique formula Fucoidan to an impressive maximum of 96%.
‘’Any opinions, findings, conclusions or recommendations expressed in this material/event (or by members of the project team) do not reflect the views of the Government of the Hong Kong Special Administrative Region or the Innovation and Technology Commission.’’
#HKPC #HKIB #CUHK